• Transcranial Magnetic Stimulation (TMS) in Multiple Sclerosis

  NCT04062331

  Unknown statusInterventionalPhase 1Phase 2Updated Aug 21, 2019
• A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

  NCT01428726

  CompletedInterventionalPhase 2Updated Mar 18, 2014
• Safety, Tolerability, and Effectiveness of CGP77116 in Patients With Multiple Sclerosis (MS)

  NCT00001781

  CompletedInterventionalPhase 2Updated Mar 4, 2008
• A Trial to Investigate the Effectiveness of Testosterone Treatment in Men With Multiple Sclerosis

  NCT02317263

  WithdrawnInterventionalPhase 2Updated Aug 4, 2016
• Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial

  NCT01085318

  CompletedInterventionalPhase 4Updated Feb 23, 2018
• Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis

  NCT00027300

  CompletedInterventionalPhase 3Updated Jan 9, 2017

ClinicalTrials.gov ID

NCT03910738

Lead Sponsor

University Hospital, Strasbourg, FranceOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 2

Enrollment

40Estimated

Last Update Posted

Jun 29, 2025Actual

Start Date

Oct 29, 2019Actual

Primary Completion Date

Dec 2027Estimated

Completion Date

Dec 2027Estimated

Official Title

TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis

Brief Summary

Centra nervous system (CNF) damage in multiple sclerosis (MS), are mainly attributed to myelin destruction, axonal abnormalities and subsequent degeneration, and are responsible for serious deficiencies. Current therapies are focused on the treatment of inflammation with several types of anti-inflammatory agents. However, there is an urgent need for innovative therapies promoting neuroregeneration and particularly myelin repair.

It has been demonstrated that testosterone can act through neural androgen receptors to promote proliferation and differentiation of oligodendrocyte precursors into mature oligodendrocytes in a cuprizone-induced animal model of demyelination. The rare clinical trials on testosterone are mainly exploratory. Here, we sought to demonstrate an effect of testosterone supplementation in testosterone-deficient patients in a multicenter, randomized, parallel-group, double-blind, placebo-controlled phase 2 trial.

The main objective will be to determine the neuroprotective and remyelinating effects of testosterone using tensor diffusion imaging techniques and thalamic atrophy analyzes.

As secondary objectives, we would like to study the impact of testosterone supplementation on other conventional and unconventional MRI parameters and on clinical outcomes (cognition, fatigue, quality of life, impact on work / activity and anxiety / depression).

• Multiple Sclerosis, Relapsing-Remitting

• Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection
• Placebo 4 mL Solution for Injection
• MRI
• Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities
• Assessment of disability

Ages Eligible for Study

Adult (18-64)

Sexes Eligible for Study

Male

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Man between 18 and 55 years
• Patient affiliated to a social health insurance plan
• Patient able to understand the objectives and risks related to the research and able to comply with the requirements of the protocol throughout the duration of the study
• Patient having been informed of the results of the prior medical examination
• Patient having signed an informed consent
• Confirmed and documented diagnosis of MS, as defined by the revised McDonald criteria,
• Patient who have been receiving one of the following disease modifying therapies for at least one year prior to randomization: natalizumab , fingolimod, ponesimod, ocrelizumab, or ofatumumab, in accordance with their prescribing information. Switching from one molecule to another during the previous year is also permitted, provided that the switch was motivated by a non-neurological reason (relapse, MRI activity). Patients receiving ocrelizumab within 6 to 9 months are eligible, provided they have received full-dose ocrelizumab for at least 2 years.
• Biological hypogonadism defined by serum total testosterone levels below 20 nmol / L (checked by blood sampling during the screening visit)
• For patients under natalizumab : Negative status for JC virus or JC virus synthesis index ≤ 1.5 (checked by blood sampling at the inclusion visit)
• No relapses in the year prior to inclusion
• Disability status during the selection visit with an EDSS score of 0 to 7 (verified by questionnaire during the inclusion visit)
• Stable neurological state in the month preceding randomization

Exclusion Criteria:

• Patients with progressive MS (primary or secondary)
• Patients with hypogonadism with clinical symptoms and treated with androgens
• Patients with PSA (prostate specific antigen)> 2.5 ng / ml (for an age less than 49 years old) or > 3.5 ng / ml (for age ≥ 50 years) (checked by a blood test at the inclusion visit)
• Patients with a hematocrit level > 54% (checked by blood sampling during the inclusion visit)
• Patients refusing or unable to undergo an MRI
• Patients with any other disease other than MS that may contribute to neurological symptoms and signs or affect their evaluation
• Patients with neurological signs compatible with progressive multifocal leukoencephalopathy (PML) or confirmed leukoencephalopathy
• Patients diagnosed with untreated sleep apnea
• Patients with or having had cancer or tumors of the liver, heart, kidney, prostate or mammary gland
• Patients with cardiovascular, renal, hepatic, hematological, gastrointestinal, pulmonary, uncontrolled diseases
• Patients wishing to procreate during the study period
• Patients with chronic infectious disease
• Patients with organic or psychiatric disease compromise their ability to understand the information given and to follow the protocol
• Patients with a history of hypersensitivity to treatment or any of the excipients, or drugs of similar chemical classes
• Patients who used experimental drugs and / or who participated in clinical drug trials in the 6 months prior to selection
• Patient in exclusion period (determined by previous study or in progress)
• Impossibility of giving information to the patient (subject in emergency situation, difficulties in understanding the subject or other)
• Incapacitated subject (subject to a legal protection measure: safeguard of justice, curatorship, guardianship, future protection mandate, family habilitation)

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Quadruple

Lead Sponsor

University Hospital, Strasbourg, FranceOTHER

Collaborators

BayerINDUSTRY

Fédération Hospitalo-Universitaire NEUROGENYCSUNKNOWN

Grünenthal GmbHINDUSTRY

g.mathey@chru-nancy.fr+333 83 85 16 88